Citations (109)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Qianyu Zhang, Wen Wu, Jinqiang Zhang & Xuefeng Xia. (2021) Merits of the ‘good’ viruses: the potential of virus-based therapeutics. Expert Opinion on Biological Therapy 21:6, pages 731-740.
Read now
Read now
Hussein Y Naim. (2015) Measles virus. Human Vaccines & Immunotherapeutics 11:1, pages 21-26.
Read now
Read now
Sean M. Geary & Aliasger K. Salem. (2013) Prostate cancer vaccines. OncoImmunology 2:5.
Read now
Read now
Amando Zuniga, Mathias Liniger, Teldja Neige Azzouz Morin, René R. Marty, Marian Wiegand, Orhan Ilter, Sara Weibel, Martin A. Billeter, Marlyse C. Knuchel & Hussein Y. Naim. (2013) Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Human Vaccines & Immunotherapeutics 9:3, pages 607-613.
Read now
Read now
Hussein Y. Naim. (2013) Applications and challenges of multivalent recombinant vaccines. Human Vaccines & Immunotherapeutics 9:3, pages 457-461.
Read now
Read now
Silvia Baroncelli, Donatella RM Negri, Zuleika Michelini & Andrea Cara. (2008) Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Review of Vaccines 7:9, pages 1419-1434.
Read now
Read now
Amit K Goyal, Kapil Khatri, Neeraj Mishra & Suresh P Vyas. (2008) New patents on mucosal delivery of vaccines. Expert Opinion on Therapeutic Patents 18:11, pages 1271-1288.
Read now
Read now
Rory D de Vries, Koert J Stittelaar, Albert DME Osterhaus & Rik L de Swart. (2008) Measles vaccination: new strategies and formulations. Expert Review of Vaccines 7:8, pages 1215-1223.
Read now
Read now
Thomas M Luby. (2008) Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Review of Vaccines 7:7, pages 995-1003.
Read now
Read now
L Jean Patterson & Marjorie Robert-Guroff. (2008) Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opinion on Biological Therapy 8:9, pages 1347-1363.
Read now
Read now
Pritish K Tosh & Gregory A Poland. (2008) Emerging vaccines for influenza. Expert Opinion on Emerging Drugs 13:1, pages 21-40.
Read now
Read now
Articles from other publishers (98)
Narjess Bostanghadiri, Pardis Ziaeefar, Morvarid Golrokh Mofrad, Parsa Yousefzadeh, Ali Hashemi & Davood Darban-Sarokhalil. (2023) COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development. BioMed Research International 2023, pages 1-29.
Crossref
Crossref
Anirudha Chattopadhyay, A. Abdul Kader Jailani & Bikash Mandal. (2023) Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness. Vaccines 11:8, pages 1347.
Crossref
Crossref
Yolanda Corripio-Miyar, Clair Lyle MacLeod, Iris Mair, Richard J. Mellanby, Barry D. Moore & Tom N. McNeilly. (2023) Self-Adjuvanting Calcium-Phosphate-Coated Microcrystal-Based Vaccines Induce Pyroptosis in Human and Livestock Immune Cells. Vaccines 11:7, pages 1229.
Crossref
Crossref
Rineke de Jong, Norbert Stockhofe-Zurwieden, Judith Bonsing, Kai-Fen Wang, Sarah Vandepaer, Badiaa Bouzya, Jean-François Toussaint, Ilse Dieussaert, Haifeng Song & Ann-Muriel Steff. (2022) ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves. Nature Communications 13:1.
Crossref
Crossref
Alan H. Stokes, Camille Planty, Johanne Pion, Philippe Ancian, Alexandra Rogue, Carine Bansard, Jérémy Silvano, Dominique Papineau, Nawel Ben Abdeljelil, Giulietta Maruggi, Haifeng Song, Catherine Spickler, Karine Blouin, Guillaume Dubois, Luis-Alexander Rodriguez, Judith Baumeister, Ann-Muriel Steff & Eric Destexhe. (2022) Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus Vaccine Candidate Evaluated in Rabbits and Rats. International Journal of Toxicology 41:4, pages 263-275.
Crossref
Crossref
Safoura Soleymani, Amin Tavassoli & Mohammad Reza Housaindokht. (2022) An overview of progress from empirical to rational design in modern vaccine development, with an emphasis on computational tools and immunoinformatics approaches. Computers in Biology and Medicine 140, pages 105057.
Crossref
Crossref
Abhijeet Nayak. 2022. Microbial Engineering for Therapeutics. Microbial Engineering for Therapeutics
163
200
.
Giuliana S. Oliveira, Maria Leonor S. Oliveira, Eliane N. Miyaji & Tasson C. Rodrigues. (2021) Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines 9:11, pages 1338.
Crossref
Crossref
Rajashri Bezbaruah, Pobitra Borah, Bibhuti Bhushan Kakoti, Nizar A. Al-Shar’I, Balakumar Chandrasekaran, Da’san M. M. Jaradat, Munir A. Al-Zeer & Saeid Abu-Romman. (2021) Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Riyadi SumirtanurdinMelisa Intan Barliana. (2021) Coronavirus Disease 2019 Vaccine Development: An Overview. Viral Immunology 34:3, pages 134-144.
Crossref
Crossref
Paola Cicconi, Claire Jones, Esha Sarkar, Laura Silva-Reyes, Paul Klenerman, Catherine de Lara, Claire Hutchings, Philippe Moris, Michel Janssens, Laurence A Fissette, Marta Picciolato, Amanda Leach, Antonio Gonzalez-Lopez, Ilse Dieussaert & Matthew D Snape. (2020) First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. Clinical Infectious Diseases 70:10, pages 2073-2081.
Crossref
Crossref
Shivani Handa, Bandhul Hans, Shokhi Goel, Hafis O. Bashorun, Zach Dovey & Ashutosh Tewari. (2020) Immunotherapy in prostate cancer: current state and future perspectives. Therapeutic Advances in Urology 12, pages 175628722095140.
Crossref
Crossref
Keven Lothert, Gundula Sprick, Felix Beyer, Guiliano Lauria, Peter Czermak & Michael W. Wolff. (2020) Membrane-based steric exclusion chromatography for the purification of a recombinant baculovirus and its application for cell therapy. Journal of Virological Methods 275, pages 113756.
Crossref
Crossref
Flávia Andressa Pidone Ribeiro, Camila Pontes, Alexandre De M.V. Machado, Oscar Bruna‐Romero, Hananiah T. Quintana, Flávia De Oliveira, José Ronnie Carvalho De Vasconcelos & Daniel Araki Ribeiro. (2018)
Therapeutical effects of vaccine from
Trypanosoma cruzi
amastigote surface protein 2 by simultaneous inoculation with live parasites
. Journal of Cellular Biochemistry 120:3, pages 3373-3383.
Crossref
Crossref
Flávia Andressa Pidone Ribeiro, Camila Pontes, Ricardo T. Gazzinelli, Oscar-Bruna Romero, Mariana Cruz Lazzarin, José Fontes dos Santos, Flávia de Oliveira, Luciana Pellegrini Pisani, José Ronnie Carvalho de Vasconcelos & Daniel Araki Ribeiro. (2019) Therapeutic effects of vaccine derived from amastigote surface protein-2 (ASP-2) against Chagas disease in mouse liver. Cytokine 113, pages 285-290.
Crossref
Crossref
Mahsa Golahdooz, Sana Eybpoosh, Rouzbeh Bashar, Mahsa Taherizadeh, Behzad Pourhossein, Mohamadreza Shirzadi, Behzad Amiri & Maryam Fazeli. (2018) Comparison of Immune Responses following Intradermal and Intramuscular Rabies Vaccination Methods. Journal of Medical Microbiology and Infectious Diseases 6:4, pages 77-86.
Crossref
Crossref
Mathias Martins, Lok R. Joshi, Fernando S. Rodrigues, Deniz Anziliero, Rafael Frandoloso, Gerald F. Kutish, Daniel L. Rock, Rudi Weiblen, Eduardo F. Flores & Diego G. Diel. (2017) Immunogenicity of ORFV-based vectors expressing the rabies virus glycoprotein in livestock species. Virology 511, pages 229-239.
Crossref
Crossref
M.R. Cambronero, D. Prado-Cohrs & M. Lopez Sanroma. (2017) Basic immunological concepts applied to vaccination. Vacunas (English Edition) 18:2, pages 49-58.
Crossref
Crossref
M.R. Cambronero, D. Prado-Cohrs & M. Lopez Sanroma. (2017) Conceptos inmunológicos básicos aplicados a la vacunología. Vacunas 18:2, pages 49-58.
Crossref
Crossref
Cyrielle Fougeroux & Peter Holst. (2017) Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. International Journal of Molecular Sciences 18:4, pages 686.
Crossref
Crossref
C.L. Parks. 2017. Human Vaccines. Human Vaccines
25
63
.
David K. Clarke, R. Michael Hendry, Vidisha Singh, John K. Rose, Stephen J. Seligman, Bettina Klug, Sonali Kochhar, Lisa Marie Mac, Baevin Carbery & Robert T. Chen. (2016) Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine 34:51, pages 6597-6609.
Crossref
Crossref
Elizabeth Acosta-Ramirez, Cynthia Tram, Rachel M. Kampen, Melanie R. Tillman, Reto A. Schwendener, Zhou Xing, Scott A. Halperin & Jun Wang. (2016) Respiratory macrophages regulate CD4 T memory responses to mucosal immunization with recombinant adenovirus-based vaccines. Cellular Immunology 310, pages 53-62.
Crossref
Crossref
Gokul Swaminathan, Elizabeth A. Thoryk, Kara S. Cox, Jeffrey S. Smith, Jayanthi J. Wolf, Marian E. Gindy, Danilo R. Casimiro & Andrew J. Bett. (2016) A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates. Scientific Reports 6:1.
Crossref
Crossref
Qicheng Zhang, Zheng Liu, Jue Hou, Shuhui Wang, Chang Liu, Min Wei, Ying Liu & Yiming Shao. (2016) Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system. Vaccine 34:30, pages 3447-3453.
Crossref
Crossref
Akiko Iwasaki. (2016) Exploiting Mucosal Immunity for Antiviral Vaccines. Annual Review of Immunology 34:1, pages 575-608.
Crossref
Crossref
Fred Zepp. 2016. Vaccine Design. Vaccine Design
57
84
.
Axel Ronald Schulz, Julia Nora Mälzer, Cristina Domingo, Karsten Jürchott, Andreas Grützkau, Nina Babel, Mikalai Nienen, Tomas Jelinek, Matthias Niedrig & Andreas Thiel. (2015) Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans. The Journal of Immunology 195:10, pages 4699-4711.
Crossref
Crossref
T.J. Mahony. (2015) Understanding the molecular basis of disease is crucial to improving the design and construction of herpesviral vectors for veterinary vaccines. Vaccine 33:44, pages 5897-5904.
Crossref
Crossref
Yung-Yi C. Mosley, Ching Ching Wu & Tsang Long Lin. (2015) AVIAN VIRAL VECTOR VACCINES FOR INFECTIOUS BURSAL DISEASE. Taiwan Veterinary Journal 41:03, pages 153-163.
Crossref
Crossref
J. Rahn, D. Hoffmann, T.C. Harder & M. Beer. (2015) Vaccines against influenza A viruses in poultry and swine: Status and future developments. Vaccine 33:21, pages 2414-2424.
Crossref
Crossref
Piergiuseppe Nestola, Cristina Peixoto, Ricardo R. J. S Silva, Paula M. Alves, José P. B. Mota & Manuel J. T. Carrondo. (2015) Improved virus purification processes for vaccines and gene therapy. Biotechnology and Bioengineering 112:5, pages 843-857.
Crossref
Crossref
Alfredo G. Torres, Jai S. Rudra & Gregg N. Milligan. 2015. Vaccinology. Vaccinology
127
151
.
Angiolo Pierantoni, Maria Luisa Esposito, Virginia Ammendola, Federico Napolitano, Fabiana Grazioli, Adele Abbate, Mariarosaria del Sorbo, Loredana Siani, Anna Morena D'Alise, Alessandra Taglioni, Gemma Perretta, Antonio Siccardi, Elisa Soprana, Maddalena Panigada, Michelle Thom, Elisa Scarselli, Antonella Folgori, Stefano Colloca, Geraldine Taylor, Riccardo Cortese, Alfredo Nicosia, Stefania Capone & Alessandra Vitelli. (2015) Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Molecular Therapy - Methods & Clinical Development 2, pages 15018.
Crossref
Crossref
Thomas P. Monath, Stephen J. Seligman, James S. Robertson, Bruno Guy, Edward B. Hayes, Richard C. Condit, Jean Louis Excler, Lisa Marie Mac, Baevin Carbery & Robert T. Chen. (2015) Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine 33:1, pages 62-72.
Crossref
Crossref
Robert T. Chen, Baevin Carbery, Lisa Mac, Kenneth I. Berns, Louisa Chapman, Richard C. Condit, Jean-Louis Excler, Marc Gurwith, Michael Hendry, Arifa S. Khan, Najwa Khuri-Bulos, Bettina Klug, James S. Robertson, Stephen J. Seligman, Rebecca Sheets & Anna-Lise Williamson. (2015) The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine 33:1, pages 73-75.
Crossref
Crossref
Steven M. Fine. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
1981
1983.e1
.
Chengrong Bian, Shuzhen Liu, Na Liu, Guangzhou Zhang, Li Xing, Yingwei Song, Yueqiang Duan, Hongjing Gu, Ya Zhou, Peirui Zhang, Zhiwei Li, Keming Zhang, Zhaohai Wang, Shaogeng Zhang, Xiliang Wang & Penghui Yang. (2014) Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Research 104, pages 110-117.
Crossref
Crossref
Xinsheng Zhang, Olivia Wallace, Kevin J. Wright, Martin Backer, John W. Coleman, Rebecca Koehnke, Esther Frenk, Arban Domi, Maria J. Chiuchiolo, Joanne DeStefano, Sandeep Narpala, Rebecca Powell, Gavin Morrow, Cesar Boggiano, Timothy J. Zamb, C. Richter King & Christopher L. Parks. (2013) Membrane-bound SIV envelope trimers are immunogenic in ferrets after intranasal vaccination with a replication-competent canine distemper virus vector. Virology 446:1-2, pages 25-36.
Crossref
Crossref
Christopher L. Parks, Louis J. Picker & C. Richter King. (2013) Development of replication-competent viral vectors for HIV vaccine delivery. Current Opinion in HIV and AIDS 8:5, pages 402-411.
Crossref
Crossref
Sean M. Geary, Caitlin D. Lemke, David M. Lubaroff & Aliasger K. Salem. (2013) The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System. PLoS ONE 8:6, pages e67904.
Crossref
Crossref
Tessa M. Lawrence, Celestine N. Wanjalla, Emily A. Gomme, Christoph Wirblich, Anthony Gatt, Elena Carnero, Adolfo García-Sastre, Douglas S. Lyles, James P. McGettigan & Matthias J. Schnell. (2013) Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS ONE 8:6, pages e67123.
Crossref
Crossref
Rafael Polidoro Alves Barbosa, Bruno Galvão Filho, Luara Isabela dos Santos, Policarpo Ademar Sales Junior, Pedro Elias Marques, Rafaela Vaz Sousa Pereira, Denise Carmona Cara, Oscar Bruña-Romero, Maurício Martins Rodrigues, Ricardo Tostes Gazzinelli & Alexandre Vieira Machado. (2013) Vaccination Using Recombinants Influenza and Adenoviruses Encoding Amastigote Surface Protein-2 Are Highly Effective on Protection against Trypanosoma cruzi Infection. PLoS ONE 8:4, pages e61795.
Crossref
Crossref
Raquel Tayar Nogueira, Alanderson Rocha Nogueira, Mirian Claudia Souza Pereira, Maurício Martins Rodrigues, Patrícia Cristina da Costa Neves, Ricardo Galler & Myrna Cristina Bonaldo. (2013) Recombinant Yellow Fever Viruses Elicit CD8+ T Cell Responses and Protective Immunity against Trypanosoma cruzi. PLoS ONE 8:3, pages e59347.
Crossref
Crossref
Sean M. Geary, Caitlin D. Lemke, David M. Lubaroff & Aliasger K. Salem. (2013) Proposed mechanisms of action for prostate cancer vaccines. Nature Reviews Urology 10:3, pages 149-160.
Crossref
Crossref
Xianyong Liu, Jun Zou, Guangwen Yin, Huali Su, Xiaoxi Huang, Jianan Li, Li Xie, Yingqiong Cao, Yujuan Cui & Xun Suo. (2013) Development of transgenic lines of Eimeria tenella expressing M2e-enhanced yellow fluorescent protein (M2e-EYFP). Veterinary Parasitology 193:1-3, pages 1-7.
Crossref
Crossref
Rebecca J. Loomis & Philip R. Johnson. 2013. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines
307
324
.
Avinash K. Shetty & Yvonne A. Maldonado. 2013. Vaccinophobia and Vaccine Controversies of the 21st Century. Vaccinophobia and Vaccine Controversies of the 21st Century
15
49
.
Matthias Liniger, Artur Summerfield & Nicolas Ruggli. (2012) MDA5 Can Be Exploited as Efficacious Genetic Adjuvant for DNA Vaccination against Lethal H5N1 Influenza Virus Infection in Chickens. PLoS ONE 7:12, pages e49952.
Crossref
Crossref
Amulya K. Panda. (2012) Nanotechnology in Vaccine Development. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 82:S1, pages 13-27.
Crossref
Crossref
Carolien E. van de Sandt, Joost H. C. M. Kreijtz & Guus F. Rimmelzwaan. (2012) Evasion of Influenza A Viruses from Innate and Adaptive Immune Responses. Viruses 4:9, pages 1438-1476.
Crossref
Crossref
Huichen Guo, Rongzeng Hao, Haisheng Qian, Shiqi Sun, Dehui Sun, Hong Yin, Zaixin Liu & Xiangtao Liu. (2012) Upconversion nanoparticles modified with aminosilanes as carriers of DNA vaccine for foot-and-mouth disease. Applied Microbiology and Biotechnology 95:5, pages 1253-1263.
Crossref
Crossref
Nelson Cesar Di Paolo, Dmitry Shayakhmetov & André Lieber. 2012. Vaccinology. Vaccinology
224
236
.
Jan Ole Kemnade, Mamatha Seethammagari, Priya Narayanan, Jonathan M Levitt, Alison A McCormick & David M Spencer. (2012) Off-the-shelf Adenoviral-mediated Immunotherapy via Bicistronic Expression of Tumor Antigen and iMyD88/CD40 Adjuvant. Molecular Therapy 20:7, pages 1462-1471.
Crossref
Crossref
Jessica O. Josefsberg & Barry Buckland. (2012) Vaccine process technology. Biotechnology and Bioengineering 109:6, pages 1443-1460.
Crossref
Crossref
Niall McMullan. 2012. Molecular and Cellular Therapeutics. Molecular and Cellular Therapeutics
286
303
.
Sokunthea Top, Gilles Foucras, Martine Deplanche, Germain Rives, Jérôme Calvalido, Loic Comtet, Stéphane Bertagnoli & Gilles Meyer. (2012) Myxomavirus as a vector for the immunisation of sheep: Protection study against challenge with bluetongue virus. Vaccine 30:9, pages 1609-1616.
Crossref
Crossref
Jin Huk Choi, Joe Dekker, Stephen C. Schafer, Jobby John, Craig E. Whitfill, Christopher S. Petty, Eid E. Haddad & Maria A. Croyle. (2012) Optimized Adenovirus-Antibody Complexes Stimulate Strong Cellular and Humoral Immune Responses against an Encoded Antigen in Naïve Mice and Those with Preexisting Immunity. Clinical and Vaccine Immunology 19:1, pages 84-95.
Crossref
Crossref
Yen-Ju Shen, Enid Shephard, Nicola Douglass, Nicolette Johnston, Craig Adams, Carolyn Williamson & Anna-Lise Williamson. (2011) A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virology Journal 8:1.
Crossref
Crossref
J.H.C.M. Kreijtz, R.A.M. Fouchier & G.F. Rimmelzwaan. (2011) Immune responses to influenza virus infection. Virus Research 162:1-2, pages 19-30.
Crossref
Crossref
Adam E. Snook, Michael S. Magee & Scott A. Waldman. (2011) GUCY2C-targeted cancer immunotherapy: past, present and future. Immunologic Research 51:2-3, pages 161-169.
Crossref
Crossref
Jason S. Richardson, Max C. Abou, Kaylie N. Tran, Anand Kumar, Beni M. Sahai & Gary P. Kobinger. (2011) Impact of Systemic or Mucosal Immunity to Adenovirus on Ad-Based Ebola Virus Vaccine Efficacy in Guinea Pigs. The Journal of Infectious Diseases 204:suppl_3, pages S1032-S1042.
Crossref
Crossref
Julia Schmitz, John Roehrig, Alan Barrett & Joachim Hombach. (2011) Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine 29:42, pages 7276-7284.
Crossref
Crossref
S. M. Geary, C. D. Lemke, D. M. Lubaroff & A. K. Salem. (2011) Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunology, Immunotherapy 60:9, pages 1309-1317.
Crossref
Crossref
Xiaotian Zhong, Zhijian Lu, Richard Zollner, Jimin Zhang, Emily Braunstein, Narender Kalyan & Maninder Sidhu. 2011. Development of Vaccines. Development of Vaccines
243
259
.
E S Gabitzsch, Y Xu, S Balcaitis, J P BalintJrJr & F R Jones. (2011) An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Therapy 18:5, pages 326-335.
Crossref
Crossref
Lingling Shan, Jianpeng Xue, Jing Guo, Zhiyu Qian, Samuel Achilefu & Yueqing Gu. (2011) Improved Targeting of Ligand-Modified Adenovirus as a New Near Infrared Fluorescence Tumor Imaging Probe. Bioconjugate Chemistry 22:4, pages 567-581.
Crossref
Crossref
A. Sistigu, L. Bracci, M. Valentini, E. Proietti, R. Bona, D.R.M. Negri, A.R. Ciccaglione, E. Tritarelli, R. Nisini, M. Equestre, A. Costantino, C. Marcantonio, S.M. Santini, C. Lapenta, S. Donati, P. Tataseo, M. Miceli, A. Cara & M. Federico. (2011) Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine 29:18, pages 3465-3475.
Crossref
Crossref
. (2011) Crystal ball – 2011. Microbial Biotechnology 4:2, pages 109-137.
Crossref
Crossref
Anja Krause & Stefan Worgall. (2011) Delivery of antigens by viral vectors for vaccination. Therapeutic Delivery 2:1, pages 51-70.
Crossref
Crossref
Fred Zepp. (2010) Principles of vaccine design—Lessons from nature. Vaccine 28, pages C14-C24.
Crossref
Crossref
Maurizio Federico. (2010) Virus-like particles show promise as candidates for new vaccine strategies. Future Virology 5:4, pages 371-374.
Crossref
Crossref
Elizabeth S. Gabitzsch, Younong Xu, Joseph P. BalintJr.Jr., Zachary C. Hartman, H. Kim Lyerly & Frank R. Jones. (2010) Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunology, Immunotherapy 59:7, pages 1131-1135.
Crossref
Crossref
José Luis Nájera, Carmen Elena Gómez, Juan García-Arriaza, Carlos Oscar Sorzano & Mariano Esteban. (2010) Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens. PLoS ONE 5:6, pages e11406.
Crossref
Crossref
Gert Zimmer. (2010) RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis. Viruses 2:2, pages 413-434.
Crossref
Crossref
Rogier Bodewes, Albert Osterhaus & Guus Rimmelzwaan. (2010) Targets for the Induction of Protective Immunity Against Influenza A Viruses. Viruses 2:1, pages 166-188.
Crossref
Crossref
STEVEN M. FINE. 2010. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
2245
2247
.
Anna P. Durbin & Stephen S. Whitehead. 2010. Dengue Virus. Dengue Virus
129
143
.
Rebekka Kohlmann, Sarah Schwannecke, Bettina Tippler, Nicola Ternette, Vladimir V. Temchura, Matthias Tenbusch, Klaus Überla & Thomas Grunwald. (2009) Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus. Journal of Virology 83:23, pages 12601-12610.
Crossref
Crossref
Paola Di Bonito, Felicia Grasso, Stefania Mochi, Linda Petrone, Emanuele Fanales-Belasio, Arianna Mei, Armando Cesolini, Giuseppe Laconi, Heinke Conrad, Helga Bernhard, Claudia J. Dembek, Antonio Cosma, Stefano M. Santini, Caterina Lapenta, Simona Donati, Claudia Muratori, Colomba Giorgi & Maurizio Federico. (2009) Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395:1, pages 45-55.
Crossref
Crossref
Rogier Bodewes, Joost HCM Kreijtz & Guus F Rimmelzwaan. (2009) Yearly influenza vaccinations: a double-edged sword?. The Lancet Infectious Diseases 9:12, pages 784-788.
Crossref
Crossref
Shervin Bahrami & Finn Skou Pedersen. 2009. Delivery Technologies for Biopharmaceuticals. Delivery Technologies for Biopharmaceuticals
93
112
.
Jun Liu, Nicholas Ngai, Geoffrey W. Stone, Feng Yun Yue & Mario A. Ostrowski. (2009) The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 27:37, pages 5077-5084.
Crossref
Crossref
Ravi Singh & Kostas Kostarelos. (2009) Designer adenoviruses for nanomedicine and nanodiagnostics. Trends in Biotechnology 27:4, pages 220-229.
Crossref
Crossref
Demian Bellido, Patricio O. Craig, Marina V. Mozgovoj, Diego D. Gonzalez, Andrés Wigdorovitz, Fernando A. Goldbaum & María José Dus Santos. (2009) Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system. Vaccine 27:1, pages 136-145.
Crossref
Crossref
Steven Patterson, Timos Papagatsias & Adel Benlahrech. 2009. Dendritic Cells. Dendritic Cells
275
293
.
F. Pappalardo, M. D. Halling-Brown, N. Rapin, P. Zhang, D. Alemani, A. Emerson, P. Paci, P. Duroux, M. Pennisi, A. Palladini, O. Miotto, D. Churchill, E. Rossi, A. J. Shepherd, D. S. Moss, F. Castiglione, M. Bernaschi, M.-P. Lefranc, S. Brunak, S. Motta, P.-L. Lollini, K. E. Basford & V. Brusic. (2008) ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Briefings in Bioinformatics 10:3, pages 330-340.
Crossref
Crossref
Thorsten Demberg, Jean D. Boyer, Nina Malkevich, L. Jean Patterson, David Venzon, Ebonita L. Summers, Irene Kalisz, V. S. Kalyanaraman, Eun Mi Lee, David B. Weiner & Marjorie Robert-Guroff. (2008)
Sequential Priming with Simian Immunodeficiency Virus (SIV) DNA Vaccines, with or without Encoded Cytokines, and a Replicating Adenovirus-SIV Recombinant Followed by Protein Boosting Does Not Control a Pathogenic SIV
mac251
Mucosal Challenge
. Journal of Virology 82:21, pages 10911-10921.
Crossref
Crossref
Maria A. Croyle, Ami Patel, Kaylie N. Tran, Michael Gray, Yi Zhang, James E. Strong, Heinz Feldmann & Gary P. Kobinger. (2008) Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice. PLoS ONE 3:10, pages e3548.
Crossref
Crossref
Kaifan Dai, Ying Liu, Mingjie Liu, Jianqing Xu, Wei Huang, Xianggang Huang, Lianxing Liu, Yanmin Wan, Yanling Hao & Yiming Shao. (2008) Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26:39, pages 5062-5071.
Crossref
Crossref
Jun Liu, Qigui Yu, Geoffrey W. Stone, Feng Yun Yue, Nicholas Ngai, R. Brad Jones, Richard S. Kornbluth & Mario A. Ostrowski. (2008) CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 26:32, pages 4062-4072.
Crossref
Crossref
Gábor Nagy, Levente Emo˝dy & Tibor Pál. (2008) Strategies for the development of vaccines conferring broad-spectrum protection. International Journal of Medical Microbiology 298:5-6, pages 379-395.
Crossref
Crossref
Liane Ülper, Inga Sarand, Kai Rausalu & Andres Merits. (2008) Construction, properties, and potential application of infectious plasmids containing Semliki Forest virus full-length cDNA with an inserted intron. Journal of Virological Methods 148:1-2, pages 265-270.
Crossref
Crossref
David Cooper, Kevin J. Wright, Priscilla C. Calderon, Min Guo, Farooq Nasar, J. Erik Johnson, John W. Coleman, Margaret Lee, Cheryl Kotash, Irene Yurgelonis, Robert J. Natuk, R. Michael Hendry, Stephen A. Udem & David K. Clarke. (2008) Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice. Journal of Virology 82:1, pages 207-219.
Crossref
Crossref
Rino Rappuoli. (2007) Bridging the knowledge gaps in vaccine design. Nature Biotechnology 25:12, pages 1361-1366.
Crossref
Crossref
Guus F Rimmelzwaan, Ron AM Fouchier & Albert DME Osterhaus. (2007) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Current Opinion in Biotechnology 18:6, pages 529-536.
Crossref
Crossref
Marjorie Robert-Guroff. (2007) Replicating and non-replicating viral vectors for vaccine development. Current Opinion in Biotechnology 18:6, pages 546-556.
Crossref
Crossref
Erik Rollman, Miranda Z. Smith, Andrew G. Brooks, Damian F. J. Purcell, Bartek Zuber, Ian A. Ramshaw & Stephen J. Kent. (2007) Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies. The Journal of Immunology 179:7, pages 4571-4579.
Crossref
Crossref